Clinical implications of growth hormone release inhibiting hormone (GH-RIH).
D000172:Acromegaly / Q000188:drug therapy*; D007516:Adenoma, Islet Cell / Q000188:drug therapy; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D001984:Bronchial Neoplasms / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005755:Gastrins / Q000378:metabolism; D005934:Glucagon / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D013004:Somatostatin / Q000009:adverse effects / Q000494:pharmacology*; D013972:Thyrotropin / Q000378:metabolism; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D005755:Gastrins; D013004:Somatostatin; D000324:Adrenocorticotropic Hormone; D013972:Thyrotropin; D013006:Growth Hormone; D005934:Glucagon